|Last Price$37.70||Day Change (%)0.16%|
|Open Price$37.60||Day Change ($)0.06|
|Day Range37.50–37.90||52-Week Range34.77–41.94|
As of Mon 7/27/2015 7:15:00 PM | USD
Baxter International Second Quarter 2015 Financial Results Conference Call
Research and Markets: Ventricular Fibrillation - Global Clinical Trials Review, H1, 2015
Baxter Announces Pricing of Debt Tender Offers
Sales of Bonds With Floating Rates Sink
Research and Markets: Biopharmaceuticals - Global Strategic Business Report 2015: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines
Allergan to Acquire Naurex
Research and Markets: Catheter Stabilization Device/Catheter Securement Devices Market by Product, Application, End User - Global Forecast to 2020
Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection
Although 2015 may be rocky, both Baxter and Baxalta should see significant margin expansion and growth in the long term, says Morningstar's Karen Andersen.
Despite the sector looking slightly overvalued, we still see stocks with attractive valuations across the different industries.